On June 26, 2025, Turnstone Biologics Corp. announced its merger agreement with XOMA Royalty Corporation, where shareholders will receive $0.34 per share plus contingent value rights. The transaction includes an asset sale expected to yield $3 million related to the TIDAL-01 program and involves the separation agreements with the CEO and COO for severance payments totaling approximately $1.04 million.